The Top 5 Biosimilar Articles for the Week of November 30

Here are the top 5 biosimilar articles for the week of November 30, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of November 30, 2020.

Number 5: In November, the Supreme Court heard arguments on the Affordable Care Act, Europe fired up its efforts to create a more biosimilar-friendly environment, and Genentech fought to protect its bevacizumab franchise.

Number 4: Joseph E. McClellan, PhD, MBA, discussed navigation of regulatory hurdles as Alvotech continues its quest to line up distribution partnership deals across the globe.

Number 3: Christopher Hansung Ko, PhD, president and CEO of biosimilars company Samsung Bioepis, discusses innovations and precautions the pandemic has brought to the field of biosimilars.

Number 2: A pair of simulation studies found that the wearable pegfilgrastim injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages.

Number 1: A Shanghai Henlius Biotech study demonstrates equivalence for its bevacizumab candidate, and Celltrion moves forward with a trial for a SARS-CoV-2 candidate.

To read all of these articles and more, visit centerforbiosimilars.com.